COMMUNIQUÉS West-GlobeNewswire

Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026
11/05/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized [...]
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
11/05/2026
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals LOUISVILLE, Colo., May 11, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions [...]
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
11/05/2026
Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape Segment highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to [...]
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
11/05/2026
Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on [...]
WORK Medical Collaborates with Novabioplus to Unlock Biological Data Value with AI, Advancing the “BioToken” Assetization Model
11/05/2026
Hangzhou, China, May 11, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China, through its subsidiaries in China, today [...]
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
11/05/2026
Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication DMC performed a risk-benefit assessment, identified no new [...]
HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss
11/05/2026
Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers MENLO PARK, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- PacBio ( [...]
CONVENING NOTICE TO THE ORDINARY GENERAL MEETING 2026 OF IBA SA
11/05/2026
CONVENING NOTICE TO THE ORDINARY GENERAL MEETING 2026 OF IBA SA – WEDNESDAY, JUNE 10, 2026, AT 10:00 A.M. – Dear Shareholder, We have the honor of convening you to the Ordinary General Meeting (the " OGM ") of IBA to be [...]
CONVOCATION À L’ASSEMBLÉE GÉNÉRALE ORDINAIRE 2026 DE IBA SA
11/05/2026
CONVOCATION À L’ASSEMBLÉE GÉNÉRALE ORDINAIRE 2026 DE IBA SA – MERCREDI 10 JUIN 2026, À 10H00 – Cher Actionnaire, Nous avons l’honneur de vous convoquer à l’Assemblée générale ordinaire (l’«  AGO  ») d’IBA, qui se [...]
Solésence Launches New Skin Health Technologies: WHSPR™ and Chromalüm™
11/05/2026
New platform technologies enable OTC-grade sensitive skin claims in previously inaccessible anhydrous formats and bring environmental protection deeper into the color cosmetics assortment ROMEOVILLE, Ill., May 11, 2026 [...]
MindBio Develops Fatigue Prediction Model using Speech Analytics and AI
11/05/2026
Patent application filed in World First claims. Detection of Neurologically Active Substances and Fatigue in a Human by Analysis of Voice Characteristics. Early warning technologies for the detection of neurologically [...]
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
11/05/2026
NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]
Disc Medicine to Participate in Upcoming Investor Conferences
11/05/2026
WATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
11/05/2026
Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global Crisis HOUSTON, May 11, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics [...]
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
11/05/2026
AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood [...]
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
11/05/2026
Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to [...]
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
11/05/2026
NORCROSS, Ga., May 11, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal [...]
First Participant Dosed in AskBio Phase 1/Phase 2 Gene Therapy Trial of AB-1009 for Late-Onset Pompe Disease (LOPD)
11/05/2026
Durham, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- AB-1009, an adeno-associated virus (AAV) investigational gene therapy, is being evaluated for the treatment of late-onset Pompe disease (LOPD) in the PROGRESS-GT LOPD trial [...]
Jabez Biosciences Presents First-in-Human Pharmacokinetic and Pharmacodynamic Data for JBZ-001 at AACR Annual Meeting 2026
11/05/2026
Phase 1 Clinical Data Demonstrate Dose-Proportional PK, No Dose-Limiting Toxicities Through Four Dose Levels, and Concordance with Preclinical PBPK Predictions CRANBERRY TOWNSHIP, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- [...]

Pages